Nobivac NXT FeLV

Opinion

EMA has issued an opinion on this medicine

feline leukemia (RNA particle) vaccine

Overview

On 18 June 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the veterinary medicinal product Nobivac NXT FeLV, lyophilisate and solvent for suspension for injection, intended for use in cats. The applicant for this veterinary medicinal product is Intervet International B.V.

Nobivac NXT FeLV is an immunological veterinary medicinal product (vaccine) containing feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient as the active substance.

The benefits of Nobivac NXT FeLV are its efficacy for the active immunisation of cats to reduce persistent viraemia and clinical signs caused by feline leukemia virus (FeLV).

The onset of immunity is 1 week. The duration of immunity is 1 year after primary vaccination or 3 years after re-vaccination.

Nobivac NXT FeLV is generally well tolerated at the recommended dose. The most common side effects are injection site swelling and elevated temperature (common).

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Nobivac NXT FeLV and therefore recommends the granting of the marketing authorisation.

---

Note: Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

CVMP summary of positive opinion for Nobivac NXT FeLV

Adopted Reference Number: EMA/CVMP/107685/2026

Product details

• Name of medicine:
  Nobivac NXT FeLV
• Active substance:
  feline leukemia virus (FeLV) self-amplifying RNA (saRNA)-particle: 106.6 – 109.3 RP
• International non-proprietary name (INN) or common name:
  feline leukemia (RNA particle) vaccine
• Species:
  Cats
• Anatomical therapeutic chemical veterinary (ATCvet) code:
  QI06AX
• EMA product number:
  EMEA/V/C/006683
• Marketing authorisation applicant:
  Intervet International B.V.
• Opinion adopted:
  18/06/2026
• Opinion status:
  Positive